TTVR with both, the Cardiovalve and EVOQUE prothesis is an effective treatment option, leading to profound TR reduction and meaningful clinical improvement at 30-day follow-up.
Abstract
Background Transcatheter Tricuspid Valve Replacement (TTVR) has emerged as a treatment option for patients with severe tricuspid regurgitation (TR) who are at high surgical risk and unsuitable for tricuspid transcatheter edge-to-edge repair (T-TEER). Objectives This study aims to compare procedural, clinical and echocardiographic outcomes of two different TTVR devices: the Cardiovalve (Venus MedTech) and the EVOQUE (Edwards Lifesciences) prosthesis. Methods We performed a retrospective, single-center cohort analysis including all consecutive patients who were treated with TTVR. Primary endpoints included TR reduction, NYHA class and safety events according to TVARC criteria. Results Overall, 25 consecutive patients were included in the analysis. The Cardiovalve prosthesis was implanted in 12 patients and the EVOQUE prosthesis in 13 patients. Intraprocedural success was 100%. There was a significant reduction in TR grade (4.20 vs. 0.48; p < 0.001) and NYHA class (2.72 vs. 1.88; p = 0.004) for the overall cohort at 30-day follow-up, but no differences between the two devices (TR grade 0.50 vs. 0.46; p = 0.408 and NYHA class 1.75 vs. 2.00; p = 0.813; Cardiovalve and EVOQUE respectively). Mortality rate at 30 days was 0% in both groups. One patient in each group (8.0%) required new pacemaker implantation. Conclusion TTVR with both, the Cardiovalve and EVOQUE prothesis is an effective treatment option, leading to profound TR reduction and meaningful clinical improvement at 30-day follow-up. Patient selection and long term follow up need to be the focus of future studies.
OBJECTIVES
In high-risk patients, transcatheter mitral valve replacement (TMVR) is an alternative to surgery and transcatheter edge-to-edge repair (TEER). This study aims to evaluate the mid-term results of TMVR with the Tendyne System in a real-world population at a single center.
METHODS
Between November 2018 and D...
L. Besola, Cristina Di Franco, F. Giorgi et al.· Interdisciplinary cardiovasc...· 0 citations
OBJECTIVES
Tricuspid regurgitation (TR) is associated with high morbidity and mortality. The TricValve bicaval valve system has emerged as a transcatheter option for patients with severe symptomatic TR who are not candidates for surgery or orthotopic interventions. However, its safety in patients with pre-existing card...
K. Osipenko, Iuliana Coti, Paul Werner et al.· European Journal of Cardio-T...· 0 citations
Severe tricuspid regurgitation (TR) is associated with adverse outcomes, particularly in patients with cardiac implantable electronic devices (CIEDs), in whom transvalvular leads may contribute to valve dysfunction. Evidence supporting tricuspid transcatheter edge-to-edge repair (T-TEER) in this population remains limi...
Lorenzo Moscato, Francesco Stabile, G. Vadalá et al.· American Journal of Cardiolo...· 0 citations
Background Transcatheter tricuspid valve interventions (TTVIs) have recently received commercial approval; however, contemporary adoption trends in early postapproval phase are not well described. Objectives The objectives of the study were to characterize trends in utilization of transcatheter tricuspid edge-to-edge r...
Bharat Rawlley, Maximilian Reisinger, Hannah R. Murphy et al.· JACC: Advances· 0 citations
TEER was associated with a greater reduction in right atrial pressure and more favorable RV remodeling at 30 days, as opposed to TTVR, which achieved more complete and sustained elimination of tricuspid regurgitation with higher forward stroke volume.
Mohamad S. Alabdaljabar, Mohamed Elhadi, J. Thaden et al.· Journal of the American Hear...· 0 citations
The feasibility of TTVR in elderly patients with complex anatomy is demonstrated and effective in selected elderly high-risk patients with severe TR and challenging anatomy and delayed conduction disturbances as a clinically important complication requiring extended rhythm surveillance are highlighted.
L. Trabucchi, Sergio Torralbas Fitz, Rodolfo Arce et al.· JACC Case Reports· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.